» Articles » PMID: 26273686

A Randomized Controlled Trial of Exercise in Spinal and Bulbar Muscular Atrophy

Abstract

Objective: To determine the safety and efficacy of a home-based functional exercise program in spinal and bulbar muscular atrophy (SBMA).

Methods: Subjects were randomly assigned to participate in 12 weeks of either functional exercises (intervention) or a stretching program (control) at the National Institutes of Health in Bethesda, MD. A total of 54 subjects enrolled, and 50 completed the study with 24 in the functional exercise group and 26 in the stretching control group. The primary outcome measure was the Adult Myopathy Assessment Tool (AMAT) total score, and secondary measures included total activity by accelerometry, muscle strength, balance, timed up and go, sit-to-stand test, health-related quality of life, creatine kinase, and insulin-like growth factor-1.

Results: Functional exercise was well tolerated but did not lead to significant group differences in the primary outcome measure or any of the secondary measures. The functional exercise did not produce significantly more adverse events than stretching, and was not perceived to be difficult. To determine whether a subset of the subjects may have benefited, we divided them into high and low functioning based on baseline AMAT scores and performed a post hoc subgroup analysis. Low-functioning individuals receiving the intervention increased AMAT functional subscale scores compared to the control group.

Interpretation: Although these trial results indicate that functional exercise had no significant effect on total AMAT scores or on mobility, strength, balance, and quality of life, post hoc findings indicate that low-functioning men with SBMA may respond better to functional exercises, and this warrants further investigation with appropriate exercise intensity.

Citing Articles

Therapeutic targeting of the polyglutamine androgen receptor in Spinal and Bulbar Muscular Atrophy.

Sangotra A, Lieberman A Expert Opin Ther Targets. 2025; 29(1-2):29-41.

PMID: 39915972 PMC: 11888889. DOI: 10.1080/14728222.2025.2464173.


Functional Outcome Measures to Optimize Drug Development in Spinal and Bulbar Muscular Atrophy: Results From a Meta-Analysis of the Global SBMA Dataset.

Huggett S, Tebbenkamp A, Rinaldi C, Jayaseelan D, Zampedri L, Blasi L Neurology. 2024; 103(12):e210088.

PMID: 39591556 PMC: 11666247. DOI: 10.1212/WNL.0000000000210088.


Exercise attenuates polyglutamine-mediated neuromuscular degeneration in a mouse model of spinal and bulbar muscular atrophy.

Hirunagi T, Nakatsuji H, Sahashi K, Yamamoto M, Iida M, Tohnai G J Cachexia Sarcopenia Muscle. 2023; 15(1):159-172.

PMID: 37937369 PMC: 10834330. DOI: 10.1002/jcsm.13344.


The use of digital outcome measures in clinical trials in rare neurological diseases: a systematic literature review.

Poleur M, Markati T, Servais L Orphanet J Rare Dis. 2023; 18(1):224.

PMID: 37533072 PMC: 10398976. DOI: 10.1186/s13023-023-02813-3.


Long-term effects of the gait treatment using a wearable cyborg hybrid assistive limb in a patient with spinal and bulbar muscular atrophy: a case report with 5 years of follow-up.

Iijima K, Watanabe H, Nakashiro Y, Iida Y, Nonaka M, Moriwaka F Front Neurol. 2023; 14:1143820.

PMID: 37360345 PMC: 10285061. DOI: 10.3389/fneur.2023.1143820.


References
1.
Kenney K, Landau M, Gonzalez R, Hundertmark J, OBrien K, Campbell W . Serum creatine kinase after exercise: drawing the line between physiological response and exertional rhabdomyolysis. Muscle Nerve. 2012; 45(3):356-62. DOI: 10.1002/mus.22317. View

2.
Krivickas L . Exercise in neuromuscular disease. J Clin Neuromuscul Dis. 2008; 5(1):29-39. DOI: 10.1097/00131402-200309000-00004. View

3.
Heil D . Predicting activity energy expenditure using the Actical activity monitor. Res Q Exerc Sport. 2006; 77(1):64-80. DOI: 10.1080/02701367.2006.10599333. View

4.
. Muscular weakness assessment: use of normal isometric strength data. The National Isometric Muscle Strength (NIMS) Database Consortium. Arch Phys Med Rehabil. 1996; 77(12):1251-5. DOI: 10.1016/s0003-9993(96)90188-4. View

5.
Fernandez-Rhodes L, Kokkinis A, White M, Watts C, Auh S, Jeffries N . Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol. 2011; 10(2):140-7. PMC: 3056353. DOI: 10.1016/S1474-4422(10)70321-5. View